131 related articles for article (PubMed ID: 1943727)
1. The effect of CP 68,722, a thiozolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats.
Bowen L; Stein PP; Stevenson R; Shulman GI
Metabolism; 1991 Oct; 40(10):1025-30. PubMed ID: 1943727
[TBL] [Abstract][Full Text] [Related]
2. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
Upton R; Widdowson PS; Ishii S; Tanaka H; Williams G
Br J Pharmacol; 1998 Dec; 125(8):1708-14. PubMed ID: 9886762
[TBL] [Abstract][Full Text] [Related]
3. Effect of the new oral antidiabetic agent (-)-BM 13.0913.Na on insulin resistance in lean and obese Zucker rats.
Apweiler R; Kühnle HF; Ritter G; Schell R; Freund P
Metabolism; 1995 May; 44(5):577-83. PubMed ID: 7752904
[TBL] [Abstract][Full Text] [Related]
4. Lipid lowering explains the insulin sensitivity enhancing effects of a thiazolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione.
Yakubu-Madus FE; Stephens TW; Johnson WT
Diabetes Obes Metab; 2000 Jun; 2(3):155-63. PubMed ID: 11220551
[TBL] [Abstract][Full Text] [Related]
5. Interstitial muscle insulin and glucose levels in normal and insulin-resistant Zucker rats.
Holmäng A; Mimura K; Björntorp P; Lönnroth P
Diabetes; 1997 Nov; 46(11):1799-804. PubMed ID: 9356029
[TBL] [Abstract][Full Text] [Related]
6. Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats.
Bergeron R; Previs SF; Cline GW; Perret P; Russell RR; Young LH; Shulman GI
Diabetes; 2001 May; 50(5):1076-82. PubMed ID: 11334411
[TBL] [Abstract][Full Text] [Related]
7. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.
Oakes ND; Thalén PG; Jacinto SM; Ljung B
Diabetes; 2001 May; 50(5):1158-65. PubMed ID: 11334421
[TBL] [Abstract][Full Text] [Related]
8. Effects of troglitazone on dexamethasone-induced insulin resistance in rats.
Okumura S; Takeda N; Takami K; Yoshino K; Hattori J; Nakashima K; Sugimoto M; Ishimori M; Takami R; Yasuda K
Metabolism; 1998 Mar; 47(3):351-4. PubMed ID: 9500576
[TBL] [Abstract][Full Text] [Related]
9. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats.
Sugiyama Y; Shimura Y; Ikeda H
Arzneimittelforschung; 1990 Apr; 40(4):436-40. PubMed ID: 2192715
[TBL] [Abstract][Full Text] [Related]
10. Troglitazone improves insulin-stimulated glucose utilization associated with an increased muscle glycogen content in obese Zucker rats.
Oshida Y; Kako M; Nakai N; Shimomura Y; Li L; Sato J; Ohsawa I; Sato Y
Endocr J; 1999 Oct; 46(5):723-30. PubMed ID: 10670760
[TBL] [Abstract][Full Text] [Related]
11. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat.
Lee MK; Miles PD; Khoursheed M; Gao KM; Moossa AR; Olefsky JM
Diabetes; 1994 Dec; 43(12):1435-9. PubMed ID: 7958495
[TBL] [Abstract][Full Text] [Related]
12. Retinoid X receptor agonists have anti-obesity effects and improve insulin sensitivity in Zucker fa/fa rats.
Liu YL; Sennitt MV; Hislop DC; Crombie DL; Heyman RA; Cawthorne MA
Int J Obes Relat Metab Disord; 2000 Aug; 24(8):997-1004. PubMed ID: 10951538
[TBL] [Abstract][Full Text] [Related]
13. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.
Oakes ND; Kennedy CJ; Jenkins AB; Laybutt DR; Chisholm DJ; Kraegen EW
Diabetes; 1994 Oct; 43(10):1203-10. PubMed ID: 7926289
[TBL] [Abstract][Full Text] [Related]
14. Normalization of skeletal muscle glycogen synthesis and glycolysis in rosiglitazone-treated Zucker fatty rats: an in vivo nuclear magnetic resonance study.
Jucker BM; Schaeffer TR; Haimbach RE; McIntosh TS; Chun D; Mayer M; Ohlstein DH; Davis HM; Smith SA; Cobitz AR; Sarkar SK
Diabetes; 2002 Jul; 51(7):2066-73. PubMed ID: 12086934
[TBL] [Abstract][Full Text] [Related]
15. Effect of obesity on susceptibility to fatty acid-induced peripheral tissue insulin resistance.
Kruszynska YT; Olefsky JM; Frias JP
Metabolism; 2003 Feb; 52(2):233-8. PubMed ID: 12601639
[TBL] [Abstract][Full Text] [Related]
16. Chronic physiologic hyperinsulinemia impairs suppression of plasma free fatty acids and increases de novo lipogenesis but does not cause dyslipidemia in conscious normal rats.
Koopmans SJ; Kushwaha RS; DeFronzo RA
Metabolism; 1999 Mar; 48(3):330-7. PubMed ID: 10094109
[TBL] [Abstract][Full Text] [Related]
17. Metabolic effects of troglitazone on fat-induced insulin resistance in the rat.
Khoursheed M; Miles PD; Gao KM; Lee MK; Moossa AR; Olefsky JM
Metabolism; 1995 Nov; 44(11):1489-94. PubMed ID: 7476339
[TBL] [Abstract][Full Text] [Related]
18. Role of plasma insulin concentration in regulating glucose and lipid metabolism in lean and obese Zucker rats.
Noshiro O; Hirayama R; Shimaya A; Yoneta T; Niigata K; Shikama H
Int J Obes Relat Metab Disord; 1997 Feb; 21(2):115-21. PubMed ID: 9043965
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidinediones exert different effects on insulin resistance between dexamethasone-treated rats and wistar fatty rats.
Kimura M; Daimon M; Tominaga M; Manaka H; Sasaki H; Kato T
Endocr J; 2000 Feb; 47(1):21-8. PubMed ID: 10811289
[TBL] [Abstract][Full Text] [Related]
20. Assessment of hepatic insulin action in obese type 2 diabetic patients.
Staehr P; Hother-Nielsen O; Levin K; Holst JJ; Beck-Nielsen H
Diabetes; 2001 Jun; 50(6):1363-70. PubMed ID: 11375337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
